Total Payments
$582,558
2024 Payments
$279,692
Companies
22
Transactions
598
Medicare Patients
337
Medicare Billing
$42,654
Payment Breakdown by Category
Other$286,329 (49.2%)
Consulting$175,531 (30.1%)
Travel$93,239 (16.0%)
Food & Beverage$16,050 (2.8%)
Research$11,320 (1.9%)
Education$89.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $277,877 | 91 | 47.7% |
| Consulting Fee | $175,531 | 74 | 30.1% |
| Travel and Lodging | $93,239 | 183 | 16.0% |
| Food and Beverage | $16,050 | 226 | 2.8% |
| Unspecified | $11,320 | 20 | 1.9% |
| Honoraria | $8,452 | 3 | 1.5% |
| Education | $89.99 | 1 | 0.0% |
Payments by Type
General
$571,238
578 transactions
Research
$11,320
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $379,388 | 375 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $50,735 | 56 | $0 (2024) |
| GENZYME CORPORATION | $48,354 | 37 | $0 (2024) |
| Grifols USA, LLC | $25,690 | 26 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $18,641 | 15 | $0 (2024) |
| Pharming Healthcare, Inc. | $13,599 | 10 | $0 (2024) |
| Amgen Inc. | $9,979 | 11 | $0 (2023) |
| F. Hoffmann-La Roche AG | $5,216 | 4 | $0 (2024) |
| Blueprint Medicines Corporation | $4,855 | 6 | $0 (2023) |
| Hikma Pharmaceuticals USA | $4,676 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $279,692 | 239 | AstraZeneca Pharmaceuticals LP ($178,689) |
| 2023 | $207,557 | 209 | AstraZeneca Pharmaceuticals LP ($138,199) |
| 2022 | $24,300 | 38 | AstraZeneca Pharmaceuticals LP ($23,753) |
| 2020 | $14.99 | 1 | GlaxoSmithKline, LLC. ($14.99) |
| 2019 | $268.92 | 4 | AstraZeneca Pharmaceuticals LP ($247.11) |
| 2018 | $719.88 | 11 | GlaxoSmithKline, LLC. ($441.77) |
| 2017 | $70,005 | 96 | AstraZeneca Pharmaceuticals LP ($38,486) |
All Payment Transactions
598 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $53.71 | General |
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,875.00 | General |
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $98.41 | General |
| Category: Immunology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/22/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 11/22/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,796.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/22/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,398.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/22/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $699.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $366.95 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Respiratory | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Respiratory | ||||||
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $394.77 | General |
| Category: Respiratory | ||||||
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $372.90 | General |
| Category: Respiratory | ||||||
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $210.76 | General |
| Category: Respiratory | ||||||
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $134.78 | General |
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $117.29 | General |
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: Immunology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $64.14 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Impact of Baseline Characteristics on Long-term Response Following Omalizumab Treatment in Patients with Allergic Asthma | F. Hoffmann-La Roche AG | $2,888 | 2 |
| Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy | GENZYME CORPORATION | $2,500 | 6 |
| Impact of Patient Baseline Characteristics On Work Productivity and Activity Impairment Following Omalizumab Treatment In Patients With Allergic Asthma | F. Hoffmann-La Roche AG | $2,328 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $2,097 | 5 |
| ASP2b | SANOFI-AVENTIS U.S. LLC | $896.63 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting B2 Adrenergic Agonist (LABA) Therapy | GENZYME CORPORATION | $500.00 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | GENZYME CORPORATION | $110.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 104 | 130 | $27,703 | $13,213 |
| 2022 | 3 | 100 | 131 | $26,970 | $13,304 |
| 2021 | 2 | 65 | 84 | $16,520 | $8,504 |
| 2020 | 2 | 68 | 85 | $17,370 | $7,633 |
Total Patients
337
Total Services
430
Medicare Billing
$42,654
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 56 | 56 | $16,438 | $7,772 | 47.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 62 | $9,410 | $4,494 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 12 | $1,855 | $946.92 | 51.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 45 | 45 | $13,050 | $6,309 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 43 | 74 | $11,100 | $5,757 | 51.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $2,820 | $1,238 | 43.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 37 | 56 | $8,400 | $4,276 | 50.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $8,120 | $4,228 | 52.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 33 | 33 | $9,570 | $4,493 | 46.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 52 | $7,800 | $3,140 | 40.3% |
About Dr. Rohit Katial, MD
Dr. Rohit Katial, MD is a Allergy & Immunology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750463303.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rohit Katial, MD has received a total of $582,558 in payments from pharmaceutical and medical device companies, with $279,692 received in 2024. These payments were reported across 598 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($277,877).
As a Medicare-enrolled provider, Katial has provided services to 337 Medicare beneficiaries, totaling 430 services with total Medicare billing of $42,654. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Clinical & Laboratory Immunology
- Location Denver, CO
- Active Since 10/20/2006
- Last Updated 02/23/2021
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1750463303
Products in Payments
- FASENRA (Biological) $166,242
- TEZSPIRE (Biological) $120,024
- DUPIXENT (Biological) $96,015
- AIRSUPRA (Drug) $33,996
- Xembify (Biological) $25,747
- DUPIXENT DUPILUMAB INJECTION (Biological) $19,356
- JOENJA (Drug) $13,599
- Xolair (Biological) $5,430
- Ryaltris (Drug) $4,676
- Grastek (Biological) $4,000
- DUPIXENT (Drug) $3,104
- Hizentra (Biological) $1,803
- Puritan Bennett (Device) $1,300
- NUCALA (Biological) $502.14
- PROAIR (Drug) $268.98
- CINQAIR (Drug) $143.60
- FASENRA (Drug) $64.43
- ACTIMMUNE (Drug) $50.34
- TRELEGY ELLIPTA (Drug) $41.46
- SYMBICORT (Drug) $26.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Denver
Eileen Wang, M.d, M.D
Allergy & Immunology — Payments: $114,321
Allergy & Immunology $114,321
Dr. Bruce Lanser, Md, MD
Allergy & Immunology — Payments: $35,207
Allergy & Immunology $35,207
Dr. Rafeul Alam, Md, MD
Allergy & Immunology — Payments: $8,518
Allergy & Immunology $8,518
Anna Meyer, M.d. Ph.d, M.D. PH.D
Allergy & Immunology — Payments: $7,088
Allergy & Immunology $7,088
Monica Reddy, M.d, M.D
Allergy & Immunology — Payments: $5,664
Allergy & Immunology $5,664
Miss. Mohini Pathria
Allergy & Immunology — Payments: $3,699
Allergy & Immunology $3,699